Tradestie Institutional Equity Comparison Engine

MANE vs SYRE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SYRE Overall Edge

SYRE Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MANE trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MANE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MANE N/M vs SYRE N/M Fwd P/E
Growth & Margin Winner SYRE
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner SYRE
1Y +239.2% vs +339.1% ยท 52W Pos 77% vs 87%
Options & Structure Winner SYRE
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (10th %ile IV)
MANE US Equity
MANE
Institutional Equity
$128.05
-1.24% 1D
Market Cap N/A
1M Return +17.67%
1Y Return +239.21%
Forward P/E N/M
Unified AI Score
38.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.37
-4.45% 1D
Market Cap $9.8B
1M Return +24.37%
1Y Return +339.11%
Forward P/E N/M
Unified AI Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MANE +239.21% SYRE +339.11% Spread: +29.36 pp (MANE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MANE TTM Op. Margin: N/A SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MANE vs SYRE. Trailing 12-month operating profitability (MANE N/A vs SYRE 0.0%) and valuation multiples (MANE N/M vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MANE (0) vs SYRE (8)
Institutional Metric MANE SYRE Criterion Row Winner
Market Capitalization Scale N/A $9.8B Larger Scale SYRE
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth SYRE
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin SYRE
Net Profit Margin Profitability N/A 0.0% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency N/A -35.0% Higher ROE SYRE
52-Week Range Position Momentum 77% ($32โ€“$157) 87% ($22โ€“$111) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 80% Vol 1.74ฮฒ ยท 59% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 38.1 / 100 (SELL) 44.4 / 100 (HOLD) Higher Composite SYRE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MANE vs SYRE Buy Guide
MANE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MANE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MANE nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.